Kisspeptin: The Reproductive Hormone Peptide Explained

How Kisspeptin Fits Into the Reproductive Axis

Kisspeptin sits at the very top of what's called the hypothalamic-pituitary-gonadal (HPG) axis — the hormonal chain of command that governs puberty, the menstrual cycle, and sex hormone production in both men and women. Kisspeptin neurons in the hypothalamus release kisspeptin, which stimulates a separate set of neurons to release gonadotropin-releasing hormone (GnRH). GnRH then travels to the pituitary gland and triggers release of LH (luteinizing hormone) and FSH (follicle-stimulating hormone) — the two hormones that directly drive ovulation in women and testosterone production in men (see our overview of luteinizing hormone for more on that downstream step). In effect, kisspeptin is the trigger that starts the entire cascade, which is why it's sometimes described as the “gatekeeper” of reproductive hormone signaling.

Where the Clinical Research Stands

Two areas of active human clinical research stand out:

• IVF trigger injections. During in vitro fertilization, patients normally receive an hCG or GnRH-agonist “trigger shot” to finalize egg maturation before retrieval. Research groups — most notably a team at Imperial College London — have studied kisspeptin as an alternative trigger, with published trial data suggesting it may reduce the risk of ovarian hyperstimulation syndrome (OHSS), a potentially serious complication of conventional triggers, in patients at higher OHSS risk. This remains a clinical-trial-stage application administered under close medical supervision in a fertility clinic setting — not an approved take-home product.
• Sexual arousal and psychosexual research. Because kisspeptin neurons in the brain also interact with mood- and arousal-related circuits, researchers have studied intravenous kisspeptin's effects on brain activity and self-reported sexual and emotional responses in controlled lab settings, including in people with low sexual desire. This research is still early-stage and has been conducted under monitored clinical/research conditions, not as a self-administered product.

Kisspeptin is not currently sold as an FDA-approved prescription drug for either use. What circulates in the broader peptide market is typically an unregulated research chemical, which carries the same sourcing and quality caveats as other unapproved peptides — with the added caution that kisspeptin acts directly on the reproductive hormone axis, an area where self-directed use without medical supervision or lab monitoring carries meaningful uncertainty.

Safety Considerations

Because kisspeptin governs reproductive hormone release, its effects are not cosmetic or purely subjective — they interact directly with the menstrual cycle, ovulation timing, and sex hormone production. Clinical trials to date have generally reported it as well-tolerated at studied doses under monitored conditions, but that safety data applies to controlled clinical administration, not to unsupervised use of an unregulated product outside a research or clinical setting. Anyone with fertility goals, a hormone-sensitive condition, or interest in kisspeptin for any reason should discuss it with a reproductive endocrinologist or physician rather than sourcing it independently. For more on how peptide legal status and sourcing work generally, see our guide on whether peptides are legal.